|Articles|December 8, 2014
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Author(s)Agnes Shanley
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges
2
2025 PharmSci 360 to Showcase Essential AI Integration and Emerging Technologies
3
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
4
Managing Risk and Minimizing the Complexity of Your Global Single-Use Supply Chain
5
